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Abstract
Background: Burden of disease is a joint measure of mortality and morbidity which makes it
easier to compare health problems in which these two components enjoy different degrees of
relative importance. The objective of this study is ascertaining the burden of disease due to cancer
in Spain via the calculation of disability-adjusted life years (DALYs).
Methods: DALYs are the sum of years of life lost due to premature mortality and years lost due
to disability. World Health Organization methodology and the following sources of data were used:
the Mortality Register and Princeton Model Life Table for Years of life lost due to premature
mortality and population, incidence estimates (Spanish tumour registries and fitting of generalized
linear mixed models), duration (from data of survival in Spain from the EUROCARE-3 study and
fitting of Weibull distribution function) and disability (weights published in the literature) for Years
lost due to disability.
Results: There were 828,997 DALYs due to cancer (20.5 DALYs/1,000 population), 61% in men.
Of the total, 51% corresponded to lung, colorectal, breast, stomach and prostate cancers. Mortality
(84% of DALYs) predominated over disability. Subjects aged under 20 years accounted for 1.6%
and those aged over 70 years accounted for 30.1% of DALYs.
Conclusion: Lung, colorectal and breast cancers are responsible for the highest number of DALYs
in Spain. Even if the burden of disease due to cancer is predominantly caused by mortality, some
cancers have a significant weight of disability. Information on 2000 burden of disease due to cancer
can be useful to assess how it has evolved over time and the impact of medical advances on it in
terms of mortality and disability.
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Background
Burden of disease (BoD) is a measure of population
health which takes into account mortality and morbidity
due to different diseases and injuries [1]. Disability-
adjusted life years (DALYs) are used as a measure of BoD.
This summary indicator represents the number of years of
healthy life lost due to a disease or risk factor. It was first
employed in the Global Burden of Disease (GBD) study
undertaken by the World Health Organization (WHO)
and Harvard University [2] in 1996; since then, DALYs
have been also used to study BoD at national level [3-8].
The results of BoD studies are potentially an aid to public
health decision making, to detect areas of improvement in
information systems and to conduct cost-effectiveness
studies. Furthermore, DALYs due to a disease can be
applied to the calculation of DALYs due to a risk factor.
For instance, DALYs due to tobacco related cancers are
needed to calculate DALYs due to this exposure, and con-
sequently to estimate the potential health gain expected
from interventions that reduce tobacco consumption.
Cancer is one of the leading causes of morbidity and mor-
tality in developed countries. In Spain, it was the second
leading cause of death [9] in 2000 (and the leading cause
in men). In 2003, there were three deaths per thousand
men and 1.7 deaths per thousand women due to malig-
nant tumours.
Cancer comprises a group of malignancies that, while hav-
ing certain characteristics in common, have very different
causes and show widely differing response to treatments.
DALYs might be a useful tool for comparing the BoD of
different tumour sites, which have a different relative
weight of disability. Indeed they may be useful to study
the evolution of the two components, mortality and disa-
bility, over time.
Cancer epidemiology has been extensively studied,
mainly in terms of mortality. The increase in survival in
many malignant neoplasms means that, in addition to
mortality, it is increasingly necessary to take into account
the non-mortal consequences of disease (disability due to
the disease itself or to treatment, and the worsening of the
patient's quality of life). Accordingly, the aim of this study
was to estimate and analyse the burden of disease due to
malignant neoplasms in Spain in 2000. In order to do
this, disability-adjusted life years were used.
Methods
DALYs were calculated by applying the methodological
principles employed in the GBD study [10]. DALYs are the
result of adding years of life lost due to premature mortal-
ity (YLL) to years lost due to disability (YLD). YLL due to
cancer among all persons that die of cancer are the sum of
years that they would have lived if they had completed the
life expectancy attributed to their age at the time of their
death. YLD express the consequences of living with a less
than perfect health condition, and they are estimated
based on the length of time with that condition and any
accompanying disability. The variables needed to esti-
mate DALYs were: mortality, incidence, duration, disabil-
ity and age at diagnosis. To compute DALYs, the social
values used in the GBD study [2], namely, discount rate
(3%) and age weighting (K = 1), were applied. The com-
puter programmes used were Gesmor [11] and DisMod
[12].
Different data sources were used for each of the estimated
parameters:
1) Population: National Institute of Statistics (Instituto
Nacional de Estadística – INE). 2) Mortality: National
Institute of Statistics data file, coded as per the Interna-
tional Classification of Diseases (ICD-10); the codes
selected for each cancer are listed in Table 1. Deaths attrib-
uted to ICD-10 Group R ("ill-defined") were reassigned in
accordance with GBD study criteria [2]. Likewise, deaths
attributed to neoplasms of unspecified site (ICD-10 code
C80) and metastasis (ICD-10 codes C77, C78 and C79)
were redistributed among all malignant tumours. 3) Life
expectancy: modified level 26 of the Princeton Model Life
Table [13] was taken as the limit for calculating potential
years of life attributed to each age. 4) Incidence: Spanish
population-based cancer registries. 5) Disease duration:
Survival data in Spain from the European Cancer Regis-
tries Study on Cancer Patients' Survival and Care (EURO-
CARE-3) [14] and the US Surveillance, Epidemiology and
End Results (SEER) [15]. And 6) Disability weights: Disa-
bility Weights for Diseases in The Netherlands [16] and
Victorian Burden of Disease Study [17].
The disease model relied on the WHO-designed model
[18], using only the part corresponding to cancers that
received treatment. It was a simplification of the disease
history, describing the different stages. Duration and dis-
ability weights would be assigned for each stage. In some
tumours, the model subdivided groups by stage or size of
tumour at diagnosis and/or histological type (see addi-
tional file 1: Distribution of cancer stages at diagnosis).
The model (Figure 1) differentiated two possible cancer
evolutions: patients who would be cured of cancer and
those who would die of cancer. The cure rate was esti-
mated from the cumulative relative survival until a prede-
fined cure threshold (the time point from which a person
could be deemed to be cured). This cure threshold was
established for each cancer site as the number of years in
which interval-specific relative survival was 100% since
diagnosis was made [19,20].BMC Public Health 2009, 9:42 http://www.biomedcentral.com/1471-2458/9/42
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Table 1: Epidemiological data used to calculate Disability-Adjusted Life Years
CANCER SITE 
(ICD-10 code)
SEX MORTALITY (number of 
deaths) *
INCIDENCE (number of 
new cases) †
DURATION (years) ‡ DISABILITY
(range 0–1) §
Bladder (C67) Males 3438 12720 4.2 0.24
Females 804 1750 3.7 0.31
Brain (C71) Males 1331 1954 1.5 0.64
Females 1046 287 1.4 0.66
Breast (C50) Males 59 - - -
Females 6206 15979 4.3 0.38
Colon and rectum Males 6958 14204 3.4 0.37
(C18-C21) Females 5740 11461 3.5 0.36
Gall bladder (C23-C24) Males 517 696 1.6 0.46
Females 1000 1542 1.4 0.49
Hodgkin's disease (C81) Males 170 890 4.9 0.24
Females 135 528 4.9 0.25
Kidney (C64-C66, C68) Males 1184 1441 3.7 0.30
Females 636 1189 3.7 0.30
Leukaemias (C91-C95) Males 1750 2436 3.6 0.37
Females 1386 1852 3.6 0.36
Liver (C22) Males 2997 3081 1.1 0.38
Females 1621 1309 0.9 0.45
Lung (C33-C34) Males 16629 16690 1.4 0.68
Females 2056 2131 1.6 0.67
Melanoma (C43) Males 426 1283 3.9 0.22
Females 339 1785 4.6 0.19
Myeloma (C90) Males 827 795 3.4 0.27
Females 863 769 5.5 0.24
Non-Hodgkin's lymphoma Males 1341 3253 4.2 0.31
(C82-C85, C96) Females 1211 2209 4.2 0.31
Oesophagus (C15) Males 1675 1512 1.4 0.76
Females 260 257 1.6 0.78BMC Public Health 2009, 9:42 http://www.biomedcentral.com/1471-2458/9/42
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Incidence from 1997 to 2000 was estimated [9] on the
basis of cancer incidence data for the period 1983–1997.
Generalized linear mixed models were fitted, based on
incidence-mortality ratio. The dependent variable was the
incidence/mortality ratio and the independent variables
were age, period and province of residence. Province was
included as a random-effect term to take provincial heter-
ogeneity into account. Model parameters were obtained
by Bayesian methods, using WinBugs [21].
The distribution percentages of incident cases in the dif-
ferent subgroups were obtained from published studies
conducted in Spain [22,23], except in the case of
melanoma and leukaemias and lymphomas (which were
drawn from the Australian GBD study, after confirming its
similarity with data from Spain's 1999 Minimum Basic
Hospital Data Set [24]).
Disease duration was estimated separately for the group of
patients who were cured and for the group of patients who
died from cancer. The duration of disease was set at 5
years, following the WHO disease model, for the first
group and it was estimated by applying the WHO meth-
odology [18] for the second group. On the assumption
that time of survival followed a Weibull distribution, this
time was estimated by adjusting survival data (at 1, 3 and
10 years from diagnosis) to this distribution function
[18,25]. As survival data at 10 years were incomplete in
Spain, these were estimated by applying the ratio between
survival at 5 and 10 years in the USA [15], to survival at 5
years in Spain. Mean disease duration by age group and
sex was calculated as the mean of disease duration in the
two groups, weighted by the cure rate. The duration of
each disease stage was based on the Victorian BoD study
[17]: this establishes the duration of all stages but one,
which is then calculated as the difference between the esti-
mated total duration and the sum of the durations of all
the other stages.
A disability weight of 0 (perfect health) to 1 (death) was
applied to each of the stages through which each type of
cancer goes through. For cancers in which the disease
model is divided in subgroups with different disability
weights, global disability was calculated as the weighted
mean according to: the duration of each stage in each sub-
group, the frequency of each subgroup in the population
and the cure rate.
The midpoint of each age group was considered as the age
of diagnosis. In the open age group (over 85 years of age),
Ovary (C56-C57) Females 1759 2997 3.1 0.34
Pancreas (C25) Males 2231 1919 0.7 0.64
Females 2117 1675 0.7 0.63
Prostate (C61) Males 5894 13212 3.1 0.43
Stomach (C16) Males 4038 2896 2.3 0.62
Females 2592 3454 2.0 0.60
Thyroid (C73) Males 116 456 4.6 0.22
Females 209 1278 4.7 0.22
Uterus and cervix 
(C53-C55)
Females 1975 7164 4.2 0.26
Other malignant neoplasms Males 7137
Females 3179
ICD-10: International Classification of Diseases, 10th Revision.
* Source: National Institute of Statistics Spain (INE). National cause-of-death register, year 2000.
† Source: estimated from incidence data from regional population-based cancer registries.
‡ Source: estimated from relative survival data from the EUROCARE-3 study. Data are averages of duration in patients who die of cancer and in 
patients cured, weighted by the cure rate.
§Source: ref. 16, 17. Data are averages of the disability weight of each disease stage, weighted by its duration and then by the cure rate.
Spanish 2000 mid-year population: 19,778,785 males and 20,597,509 females (Source: National Institute of Statistics, INE).
Table 1: Epidemiological data used to calculate Disability-Adjusted Life Years (Continued)BMC Public Health 2009, 9:42 http://www.biomedcentral.com/1471-2458/9/42
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midpoint is defined by the life expectancy at 85 years, so
these figures were considered (91.22 years among women
and 90.24 among men).
Cancers that were not analysed individually were
included in the "Other malignant tumours" group. In this
case, YLD were estimated for each age and sex groups
applying the combined YLL/YLD ratio for all the other
cancers to the YLL of the "Other malignant tumours"
group according to the WHO methodology [26].
Results
The intermediate results (mortality, incidence, duration
and disability) needed to estimate DALYs are set out in
Table 1. Cure rate estimates can be seen on the additional
file 2: Cure thresholds and cure rates.
The number of DALYs lost due to cancer was 828,997 in
Spain in 2000 (61% in men). There were a total of
698,271 YLL (63% in men) and 130,726 YLD (54% in
men).
By tumour site, neoplasm of lung was responsible for the
greatest number of DALYs (20% of the total), with colon
and rectum's in second place (12%) and breast neoplasm
in third place (9%). These three tumour sites, along with
neoplasms of stomach, prostate, bladder, liver, pancreas
and leukaemias account for more than two thirds of the
total burden of disease due to cancer. Table 2 shows BoD
of different cancer sites, in males and females.
Analysing the two components of DALYs, lung cancer
accounted for the highest number of YLL (22% of all YLL
due to cancer) and colorectal cancer accounted for most
years lost due to disability (16% of all YLD due to cancer).
Figure 2 depicts the respective weights of the two BoD
components (mortality-YLL and morbidity-YLD) for each
neoplasm. While mortality outweighed disability in the
overall cancer burden, the two components were most
equally balanced in malignant neoplasm of thyroid gland
(YLL/YLD ratio: 1.2). Cancer of the bladder, prostate and
uterus and Hodgkin's disease (HD) registered a YLL/YLD
ratio of 2. Pancreatic and liver cancers were lying at the
opposite extreme (YLL/YLD: 25). Overall, YLD accounted
for 16% of DALYs (14% in men and 19% in women).
In terms of the age distribution, patients aged 65–69 years
registered the highest number of DALYs. Figure 3 repre-
sents the number of DALYs lost due to each cancer at each
age. The general pattern showed a concentration of DALYs
from the forties onwards, rising progressively to reach a
peak in the five-year period from 65 to 69 years, except in
cancers of bladder and gall bladder (70–74 years) and
prostate (75–79 years). Some cancers, such as gynaecolog-
ical tumours and melanoma, were characterized by an ear-
lier rise in DALYs, with the peak in the 50–54-age-group
or earlier. Hodgkin's disease (HD) had a characteristic
pattern, with a peak in young adults (aged 25–29 years).
Overall, patients under the age of 40 lost 9% of all DALYs
due to cancer. Leukaemias registered the highest percent-
age of DALYs from ages 0 to 19 years (15%).
Discussion
In 2000, the burden of disease due to cancer was 828,997
DALYs in Spain (21 years of disability-adjusted life lost
per 1,000 population). This figure is consistent with that
of 21 DALYs/1,000 population calculated by the WHO for
the Euro-A Region in 2000 [27]. Cancers account for 16%
of the BoD in Spain [28], the same as in the Euro-A Region
[27] and they are the second leading cause of DALYs, after
neuropsychiatric disorders (28% of the total BoD).
In Spain, the greatest BoD due to cancer is attributable to
lung, colorectal, breast, stomach and prostate cancers. The
high BoD of lung and colorectal cancers is due both to
their incidence and mortality. Even though breast cancer
causes fewer deaths, it has a high incidence (almost as
high as the incidence of lung cancer in men) and it is the
leading cause of cancer-related DALYs among women.
Malignant neoplasm of stomach continues to be an
important cause of BoD in the Spanish population,
despite the fall in its incidence and mortality in the second
half of the 20th century [9]. The elevated BoD of prostate
Diagram of disease model for estimating cancer-related  Years Lost due to Disability Figure 1
Diagram of disease model for estimating cancer-
related Years Lost due to Disability. The model differ-
entiates two groups of patients: those who do not die from 
cancer (C) and those who die from cancer (1-C). Mean sur-
vival time for the latter is estimated by fitting Weibull distri-
bution to survival data.BMC Public Health 2009, 9:42 http://www.biomedcentral.com/1471-2458/9/42
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cancer is mainly due to its high incidence and long dura-
tion, factors which make it one of the weightiest cancers
in terms of disability.
The ranking of cancers according to DALYs is similar to
that according to mortality, as it was expected given the
lethality of these diseases. However, there are some differ-
ences between these rankings. The cancer sites that gain
more positions in the ranking according to DALYs are
bladder cancer and leukaemias (6th and 7th respectively,
increasing from 8th and 9th according to mortality). Con-
versely, those that lost more positions are liver and pan-
creas cancer (8th and 9th respectively according to DALYs
and 6th and 7th according to mortality).
Table 2: Disability-Adjusted Life Years by cancer site and sex
Females Males
CANCER SITE DALY DALY/100,000 population CANCER SITE DALY DALY/100,000 population
Breast 76944 374 Lung 145499 736
Colon & rectum 43671 212 Colon & rectum 56162 284
Uterus 23217 113 Prostate 33459 169
Lung 20111 98 Stomach 31545 159
Stomach 18427 89 Bladder 28176 142
Ovary 18234 89 Liver 22176 112
Pancreas 13688 66 Leukaemias 18646 94
Leukaemias 13685 66 Pancreas 17745 90
NHL 11342 55 Brain 16908 85
Brain 10912 53 Oesophagus 16587 84
Liver 9664 47 NHL 15458 78
Gall bladder 6083 30 Kidney 10016 51
Myeloma 5667 28 Myeloma 5928 30
Kidney 5494 27 Melanoma 5476 28
B l a d d e r 4 6 5 62 3 H D 3 5 8 41 8
Melanoma 4510 22 Gall bladder 3352 17
HD 2357 11 Thyroid 1267 6
Thyroid 2300 11 Breast 438 2
Oesophagus 1850 9 Other 76760 388
Other 27003 131
TOTAL 319815 1553 TOTAL 509182 2574
Total Spanish 2000 mid-year population: 19,778,785 males and 20,597,509 females (Source: National Institute of Statistics).
DALY: Disability-Adjusted Life Years; NHL: Non-Hodgkin's lymphoma; HD: Hodgkin's disease.BMC Public Health 2009, 9:42 http://www.biomedcentral.com/1471-2458/9/42
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In all cancer sites, the mortality component gives more
weight to the BoD than the disability component. How-
ever, in some cancer sites such as thyroid, breast, bladder,
uterus, prostate and in Hodgkin's disease, more than 25%
of its BoD is due to YLD. This highlights the need to con-
sider the effects of cancer interventions on disability as
well as on mortality when assessing them.
Young people have a greater relative weight according to
cancer BoD estimates than according to cancer mortality
data: people under the age of 40 lost 9% of all cancer
DALYs, compared to 2% of all cancer deaths.
The fall in DALYs after ages 65–69 years is due to the
lower number of persons at these ages and to the fewer
YLL per death. In malignant neoplasms of gall bladder
and prostate, older age groups register maximum BoD.
Therefore, a special increase in this particular BoD is to be
expected in the future as a consequence of the ageing of
the population. In malignant neoplasms of brain, gynae-
cological tumours, melanoma, leukaemias and HD, the
age distribution of DALYs reflects an earlier incidence
than in other tumours and, in some cases, a greater aggres-
siveness of the disease at younger ages. In the case of
breast cancer, it is worthy a note that 34% of its BoD is
experienced by women under 50 years and 21% by
women older than 69. Breast cancer screening pro-
grammes are targeted to women between 50 and 69 years
of age in most of the Spanish regions. In colorectal cancer,
10% of DALYs are lost by patients between 40 and 50
years, 27% between 70 and 80 years and 12% by older
than 80 years. It is also remarkable that 45% of the BoD
attributable to melanoma is experienced by persons under
the age of 50 years (11% between 35 and 39 years). In
cancers for which population based screening pro-
grammes are feasible, information about the age distribu-
tion of their BoD could be useful for the identification of
the optimal target population.
Cancer burden of disease in Spain in 2000 Figure 2
Cancer burden of disease in Spain in 2000. Disability-Adjusted Life Years are the sum of YLL and YLD. The figure shows 
the distribution of premature mortality (YLL) and disability (YLD) by cancer site.
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There are differences in the epidemiology of cancer
between men and women. As it has been reported else-
where [3,27], men register a higher number of DALYs due
to cancer than women. Neoplasms of oesophagus, lung
and bladder predominantly affect men, who register over
80% of all DALYs for these three sites. This can be
explained by the great weight of smoking as a risk factor
for these cancers and by the higher prevalence of smoking
among men in the past [29,30]. The acquisition of smok-
ing habit by women began later [31], but has reached even
higher levels; thus, it is likely that in the next years BoD
due to smoking-related cancers will increase among
women. Malignant tumours of liver, kidney, stomach and
brain also cause a greater BoD in men. In contrast, neo-
plasms of breast, thyroid and gall bladder are responsible
for a greater BoD in women.
The disability component in cancer BoD is greater among
women than among men. This is probably due to the
higher frequency of lung and oesophageal cancer in men,
both of which are highly lethal and short in duration, and
of breast, thyroid and uterus cancer in women, all of
which are less lethal and of longer duration.
In the Australian [3] and New Zealand BoD studies [4],
the three cancers that account for the heaviest BoD are the
same as in Spain. Stomach cancer, however, ranks tenth
and seventh respectively, and neither bladder nor liver
cancer ranks among the top ten, as is the case in Spain.
The relatively high incidence of bladder tumours in Spain
has been previously described [9]. The relative weight of
melanoma in New Zealand's BoD is greater than it is in
Spain. In the Euro-A Region [27], BoD due to cancer is
similar to that of Spain, with small differences, such as the
higher relative BoD of bladder and uterus-cervix cancers
and the lower relative BoD of cancer of the pancreas in
Spain.
Estimate of BoD due to cancer for the year 2000 has some
limitations to describe the current situation. Advances in
treatment and secondary prevention may have caused a
reduction in mortality and an increase in duration of
some cancers. However, given the lack of previous data of
cancer BoD in Spain, data from 2000 are necessary to esti-
mate changes over time and to assess the influence that
medical advances may have had on mortality and disabil-
ity. In the case of cancer, this would be feasible, given that
mortality, incidence and survival data are being collected
systematically.
One of the difficulties in calculating DALYs is the estima-
tion of disability weights. Some studies have published
Distribution of Disability-Adjusted Life Years in 5-year age groups Figure 3
Distribution of Disability-Adjusted Life Years in 5-year age groups. Spain 2000.BMC Public Health 2009, 9:42 http://www.biomedcentral.com/1471-2458/9/42
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weights [16,32] that can be used to estimate BoD. Alterna-
tively, country-specific disability weights can be obtained.
The choice of disability weights may affect the final
results, in terms of absolute BoD and even the cancer
ranking. One study [33] showed that disability weights
did not have a conclusive influence on the number of
DALYs lost due to breast cancer. However, disability
weights influence could be greater in cancers with a high
disability component. In addition, it could become
greater if YLD component of BoD due to cancer were to
increase as a consequence, say, of rises in survival. Taking
these limitations into account, disability weights used in
our study were based on those of the Dutch study [16],
because they are differentiated by disease stage and calcu-
lated in a country with comparable characteristics to those
of Spain. Indeed, they are regarded as a reference for
developed countries and they are used in most BoD stud-
ies and this allows us to compare our results with theirs.
Another difficulty comes from the limited availability of
reliable data sources for mortality, incidence and dura-
tion. Mortality data of Spain have good quality. In the case
of incidence data, the main limitation is coverage of the
tumour registries. In Spain there is not a National Registry
of Cancer. Some regions have a population-based
regional registry, which covers nearly all population in the
region, but many other regions do not have it. As a result,
the Spanish population covered by registries is approxi-
mately 25% [34]. Survival data classified by tumour stage
would have allowed us to estimate disease duration more
accurately, but they are not available. Overall, the quality
of the data sources used can be regarded as adequate [14]
and they are probably the most reliable data sources avail-
able at the time of this study. Consistency of incidence,
mortality and duration data were checked and proved
using DisMod II.
The BoD of some neoplasms may be underestimated [35]
as a result of setting duration of disease at five years in the
case of patients who were cured. Cancers that may be
affected by this decision are mainly those that most fre-
quently leave sequels, such as prostate, breast, stomach,
oesophageal or colorectal cancers. The 5-year criterion
was maintained because it is conservative and in line with
the methodology of other studies [3,4,17,18,33].
Some other assumptions made in the disease model used
in the calculation of DALYs, such as duration of some of
the disease phases, are based on expert opinion. They are
the same that are applied in other BoD studies [3,4]. This
allows us to make comparisons between studies. Further-
more, given the lack of reliable data sources, we had to
estimate cure rates from survival data to construct the dis-
ease model. Even though survival data from EUROCARE-
3 study can be considered reliable, they provide some
additional uncertainty to our BoD estimate. In order to
help readers interpret our results, we have tried to describe
all assumptions and calculations made. On top of that, we
have provided bibliographic references containing this
information.
Social values applied in BoD estimates, such as age-
weighting and discount rate are another source of uncer-
tainty and have been controversial issues. We have
applied the values more frequently used in the literature.
The age-weighting gives more relevance to deaths in
young and middle age. Its main consequence is on the age
distribution pattern of BoD. In our results the age weight-
ing may have provided cancer sites more frequent in mid-
dle ages, such as breast, leukaemias, melanoma, brain and
lymphomas with higher BoD. The 3% discount rate gives
more weight to deaths that occur nearer to the present
time. This assumption may increase the proportion of
BoD due to YLD and decrease the BoD in children
(although this influence would be more relevant in coun-
tries or diseases with high childhood mortality). Given
that discount rate adds more weight to older ages and age
weighting gives less weight to this age group, their joint
influence on our results will not be crucial [36].
Some controversy exists about the relevance of making
accurate estimates of the BoD for priority setting. It is gen-
erally accepted that many criteria should be taken into
account in order to make an efficient allocation of
resources. The main advantage of DALYs with respect to
other epidemiological measures, such as mortality or
prevalence, frequently considered when establishing pri-
orities, is that DALYs provide a unified measure of mortal-
ity and disability. This could be useful to evaluate health
interventions being focused on reducing mortality, inci-
dence or both. In this sense, DALY estimates could be
used as an outcome measure when conducting cost-effec-
tiveness studies [37]. In addition, the proportion of YLD
and YLL in different diseases can be used to suggest the
most appropriate health interventions: in cases where YLL
is predominant, those targeted at preventing the appear-
ance of disease and in cases where YLD is predominant,
those targeted at reducing sequelae and at enhancing
quality of life.
Conclusion
This study provides a global view of the epidemiological
situation of cancer in Spain, reporting data on mortality,
incidence, duration and disability of all leading malignant
neoplasms. This may be useful to study the evolution of
the burden of disease linked to different cancers and to
analyse how this evolution affects mortality and disability
components. It also highlights the need to increase the
coverage of Spanish tumour registries and underscores theBMC Public Health 2009, 9:42 http://www.biomedcentral.com/1471-2458/9/42
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fact that, in addition to its associated mortality, cancer
generates considerable disability.
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